Evidence map›Paper›PMID 41942546›Full record

ArticleScientific reports2026

Impact of chemotherapy exposure on tumor mutation burden in advanced colorectal cancer.

Tomoya Sudo, Sachiko Nagasu, Toshimitsu Tanaka, Kenji Fujiyoshi, Yusuke Kawamoto, Satoshi Shimamura, Junya Fukuda, Maako Kikuchi, Hirona Shigyo, Kenichi Koushi and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomoya SudoDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan. sudou_tomoya@kurume-u.ac.jp.
Sachiko NagasuDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Toshimitsu TanakaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan.
Kenji FujiyoshiDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Yusuke KawamotoDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Satoshi ShimamuraDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Junya FukudaDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Maako KikuchiDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Hirona ShigyoDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Kenichi KoushiDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Takahiro ShigakiDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Naohiro YoshidaDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Takefumi YoshidaDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Keisuke MiwaDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.
Hironori KogaResearch Center for Innovative Cancer Therapy, Kurume University, Kurume, 830-0011, Japan.
Fumihiko FujitaDivision of Digestive Surgery, Department of Surgery, Kurume University School of Medicine, Asahi-Machi 67, Kurume, Fukuoka, 830-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The determinants of tumor mutation burden (TMB) in microsatellite-stable (MSS) colorectal cancer (CRC) remain unclear. This study examined the impact of clinical, environmental, and genomic factors on TMB in advanced CRC using comprehensive genomic profiling (CGP). Eighty-eight patients with advanced or recurrent CRC who underwent CGP were analyzed and compared with 701 MSS CRC cases from a public dataset. Associations between TMB and clinicopathological, environmental, and genomic factors were evaluated. The number of prior chemotherapy regimens was significantly associated with higher TMB. No associations were observed between TMB and alcohol use, smoking history, or specific chemotherapeutic classes. Although variants in POLE or POLD1 were detected, all were non-pathogenic and were not linked to elevated TMB. The top 3 three most frequent genes were consistent with those in the public dataset, although variant frequencies were higher in this cohort. In MSS TMB high CRC, elevated TMB may reflect cumulative treatment-related effects rather than intrinsic hypermutagenic mechanisms, highlighting the need to interpret TMB in the context of therapeutic history.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsMutationAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedAntineoplastic AgentsBiomarkers, TumorCGPChemotherapy exposureClinicopathologic factorsColorectal cancerSNVTMB

Identifiers

PMID41942546
PMCPMC13212886

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.